Novartis: Omalizumab Met All Goals In Phase III Safety Registration Study In CSU - RT

[INCIID News Feed]

<img alt="" height="1" width="1" />
Novartis: Omalizumab Met All Goals In Phase III Safety Registration Study In CSU
RTT News
Swiss drugmaker Novartis AG (NVS: Quote) Wednesday announced late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU, a chronic and ...
Novartis skin drug helps patients with chronic hivesReuters UK
Novartis reports new Phase III data showing omalizumab significantly improves ...MarketWatch (press release)

all 4 news articles &raquo;


More...